Physician profile
Stephen C Martinez
NPI 1154362804
$672.10
in general payments reported to CMS, 2019-2025
18 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.09 · 2020: $15.48 · 2021: $32.83 · 2022: $89.45 · 2023: $15.05 · 2024: $164 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.33 | 2021-2025 | |
| Novo Nordisk INC | $134.37 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $55.36 | 2024-2025 | Repatha, Repatha |
| Lilly USA, LLC | $49.12 | 2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $31.46 | 2023-2024 | Spravato |
| Exact Sciences Corporation | $27.31 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $26.47 | 2024 | |
| Xeris Pharmaceuticals, INC. | $25.26 | 2025 | Recorlev |
| Lucid Diagnostics INC. | $19.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.09 | 2025 | Farxiga |
| Dexcom, INC. | $16.89 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $15.99 | 2025 | |
| Antares Pharma, INC. | $15.48 | 2020 | |
| Sonex Health, INC. | $15.22 | 2025 | Sx-One Microknife |
| Merck Sharp & Dohme LLC | $14.98 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13.56 | 2025 | General - Pain Management |
| Recor Medical INC | $13.24 | 2024 | Paradise Renal Denervation System |
| Intrinsic Therapeutics | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.